Buradasınız

Anasayfa » Content

KRONİK HEMODİYALİZ HASTALARI İLE PERİTON DİYALİZİ HASTALARININ KLASİK KORONER RİSK FAKTÖRLERİ VE HOMOSİSTEİN DÜZEYLERİ AÇISINDAN KARŞILAŞTIRILMASI

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Comparison ofchronic hemodialysis patients and peritoneal dialysis patients İn terms oftra-ditional coronary risk factors and honıocysteine levels. Cardiovascular complications are majör factors affeeting the morbidity and mortaiity of dialysis patients. In the present study, the tradİtİonal cardiovascular risk factors and another important risk factor, homoeysteine levels, wcre invesligatcd in patients on hemodialysis (HD) therapy (n=30) and on continuous ambula-tory peritoneal dialysis (CAPD) therapy (n=3ü). The patients were searehed for family history for cardiovascular disease, smoking history, hypertension and hypervolemia, whüe serum levels of total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, homoeysteine and C-reactive protein (CRP) were measured. Serum total cholesterol, triglyceride and CRP levels were sigtıificantly elevated in CAPD patients compared to HD patients. Homoeysteine levels werc markedly inereased in both groups of patients. However, there was no difference in homoeysteine levels between the groups. In conelusion, hyperhomocysteinemia is an indepen-dent risk factor for cardiovacular disease in patients on dialysis and the modality of dialysis does not have a signİficant effect on serum homoeysteine levels.
Bookmark/Search this post with
Abstract (Original Language): 
Diyaliz hastalarında kardiyovasküler kompîikasy onlar mortalite ve morbiditcyi etkileyen en önemli faktörlerdendir. Çalışmamızda ünitemizde hemodiyaliz (HD) ve sürekli ayaktan periton diyalizi (SAPD) tedavisi gören hastaları klasik koroner risk faktörleri ve yine önemli bir risk faktörü olarak kabul edilen homosistein düzeyleri açısmdan karşılaştırdık. 30 HD ve 30 SAPD hastası aile öyküleri, sigara içimi, hipertansiyon, hİpervolemi varlığı konusunda sorgulanırken, total kolesterol, trigliserid, HDL-kolesterol, LDL-kolesterol, homosistein ve C-reak-tif protein (CRP) düzeyleri ölçüldü. Kolesterol, trigliserid vc CRP düzeyleri SAPD grubunda anlamlı olarak daha yüksek bulunurken, homosistein düzeyleri her iki grupta da kontrol grubuna göre anlamlı olarak yüksek bulunmakla birlikte, gruplar arasında anlamlı bir fark bulunamamıştır. Sonuç olarak, homosistein, diyaliz hastalarında bağımsız bir koroner risk faktörüdür ve diyaliz tedavi şekli bu riski değiştirmemektedir
FULL TEXT (PDF): 
PDF icon arastirmax-kronik-hemodiyaliz-hastalari-ile-periton-diyalizi-hastalarinin-klasik-koroner-risk-faktorleri-homosistein-duzeyleri-acisindan-karsilastirilmasi.pdf
  • 2
99-103
  • Turkish

REFERENCES

References: 

1. Bellamy MF, McDowcll IF: Putatİve mechanisms for vascular damage by homoeysteine. J Inherit Mclab Dis 1997;20:307.
2. Bergstrom J, Lindholm B: Maînutrition, curdiac disease and mortality: an integrated point of view. Anı J Kidncy Dis 1998; 32:834.
3. Chaııveau P, Chadefaııx B, Coude M, Aupelİt J, Hannc-douche T, Kamoun P, Jungers P.: Hyperhomocysteine-mİa: a risk factor for atheroselerosis in ehronic uremie patients. Kidney İni 43:sııpp! 1993; 41:72.
Ergin H.K., Alışır S., Aksoy Z.
4. Folcy RN, Parfrey PS, Hamctt JD, Kent GM, Murray DC, Barre PE.: Hypoalbumincmia, cardiac morbidity and mortality in end-stage renal disease. J Am Soc Ncphrol 19%; 7:728.
5. Kasiskc BL: Hyperlipidemia in patients with chranic renal disease. Am J Kidney Dis 1998; 32 (suppl 3):S142.
6. Levey AS, Beto JA, Coıonado BE, Eknoyan G, Foiey RN, Kasiske BL, Klag MJ, M;ıilloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wcnger NK, Wilson PW, Wright JT Jr.: Controlling ihe epidemie of cardiovascular disease in ehronic renal disease: What do we know? What do we need to İcarn? VVlıeıe do we go from here? Nalional Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32:853.
7. Maiorca R, Cancarinİ GC, Zubani R, Camcrini C, Matıili L, Brunori G, Movüli E.: CAPD viabilİly: a long-tenn comparison with hemodialysis. Perit Dial Int 1996; 16:276.
8. Moustapha A, Gupla A, Robinson K, Arheart K, Jacob-sen DW, Schreiber MJ, Dennis VW.: Prevalence and dc-lermİnants of hyperhomocysfcinemia in hemodialysis and peritoneal dialysis. Kidney lnt 1999; 55:1470.
9. Nikolakakis N, Koımali D, Tornaritis M Anastassou A, Papadakis E, Kassotakis G, Kaiatos A.: Adipose tissue latty acid composilion, serum lİpids, and serum afpha-to-copherol in conünuous ambulatory peritoneal dialysis patients living on the island of Cıete. Perit Dial Int 1999; 19:154.
10. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS.: Serum C-reactive prolein: a predictor of morla-
İity in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1998; 18:387.
11. Parfrey PS, Foley RN: The clinical epİdemiology of cardiac disease in ehronic renal failure. J Am Soc Ncphrol 1999; 10:1606,
12. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of infîammation in the predietion of cardiovascular disease in women. N Engl 3 Med 2000; 342:836.
13. Rostand RG, Kirk KA, Rutsky EA: Dialysis-associalcd ischaemic heurt disease: insights from coronary angiog-raphy. Kidney İni 1984; 25:653.
İ4. Rottembourg J: Residııa! renal fıınclion and recovery of renal funclion in patients trealed by CAPD. Kidney Int suppl 1993; 40: S106.
15. Tang L, Mamottc CD, Van Bockxmeer FM, Taylor RR: The effect of homoeysteine on DNA syntlıesis in cultu-red humaıı vascular smooth muscle. Atherosclerosis 1998; 136:169.
16. Tsai JC, Perrella MA, Yoshizumi M Hsieh CM, Haber E, Scblcgel R, Lee ME.: Promotion of vascular smooth muscİe celi grovvth by homoeysteine: a link to alherosc-ierosis. Proc NatI Acad Sci USA 1994; 91:6369.
17. US Renal Data System. USRDS 2000 Annual Dala Re-port, National Inslilutcs of Health, National Inslİtute of Diabetes and Digcstive and Kidney Discases. Bethesda, MD, 2000.
18. Van Guldcner C, Robinson K: Homoeysteine and renal disease. Semin Tlıromb Hemosl 200Ü; 26:313.

Thank you for copying data from http://www.arastirmax.com